Therapy for celiac disease mainly relies on following a gluten-free diet.
However, a serum marker for gluten intake has yet to be established.
Dr Joseph Murray and colleagues from Minnesota, USA evaluated the utility of alkylresorcinol concentrations for detecting gluten intake in studies of human and mouse.
Alkylresorcinol concentrations were compared among treated patients with celiac disease, untreated celiac disease patients and controls.
Furthermore, 7 additional celiac disease patients whose serum samples were available at diagnosis and after gluten-free diet were evaluated.
|Total alkylresorcinol concentrations were lower in patients treated with celiac disease|
|Alimentary Pharmacology & Therapeutics|
In mice studies, the team compared alkylresorcinol concentrations in the serum of 5 mice fed a regular chow, and 10 mice fed lifelong with a gluten-free chow.
In addition, the effect of adding gluten on changes of alkylresorcinol concentrations was also evaluated.
The team found that total alkylresorcinol concentrations were significantly lower in patients treated with celiac disease, compared to untreated patients or healthy controls.
Moreover, the research team observed that alkylresorcinol concentrations in celiac disease patients significantly decreased after introduction of a gluten-free diet.
In the mice, median total alkylresorcinol concentrations in serum samples of mice fed lifelong with a gluten-free chow was 1.8 nmol/L, which was further significantly increased to 16 nmol/L after 8 days of feeding with the gluten-free chow that had gluten added to it.
Dr Murray's team concludes, "Serum alkylresorcinol concentrations could be a useful marker for dietary gluten in celiac disease."